v3.26.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profits for the three months ended March 31, 2026 and 2025 were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended March 31,
(in millions)20262025202620252026202520262025
Revenues
Product Sales$708 $654 $304 $266 $227 $213 $1,239 $1,133 
Other Revenues
711 656 305 267 228 214 1,244 1,137 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)271 251 78 93 133 137 
Cost of other revenues— — — — 
Selling, general and administrative228 221 138 153 73 73 
Research and development10 22 13 11 
Segment Profit$202 $176 $66 $11 $$(7)277 180 
Corporate(161)(174)
Amortization of intangible assets(57)(67)
Other expense, net(26)(22)
Operating income (loss)33 (83)
Interest income
Interest expense(97)(94)
Loss on extinguishment of debt(1)— 
Foreign exchange and other (3)(6)
Loss before provision for income taxes$(64)$(180)
Schedule of revenues by segment and product category
Revenues by segment and product category were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended March 31,
(in millions)20262025202620252026202520262025
Pharmaceuticals$$$265 $221 $— $— $266 $222 
Devices253 235 — — 227 213 480 448 
OTC444 409 — — — — 444 409 
Branded and Other Generics10 39 45 — — 49 54 
Other revenues
$711 $656 $305 $267 $228 $214 $1,244 $1,137